supp.fit

Zeaxanthin, Lutein and Omega-3 Fatty Acids: study protocols

12 study groups took Zeaxanthin together with Lutein and Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.

Zeaxanthin: what the research found →

Dose per serving from research: Zeaxanthin

12 study groups in 10 studies say how much Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 mg to 2.5 mg, 75% of 12 study groups.

Daily doseStudy groups
500 mcg to 1 mg
2
1 mg to 2.5 mg
9
2.5 mg to 5 mg
0
5 mg to 10 mg
0
10 mg to 25 mg
0
over 25 mg
1

Dose per serving from research: Lutein

12 study groups in 10 studies say how much Lutein participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 92% of 12 study groups.

Daily doseStudy groups
5 mg to 10 mg
11
10 mg to 25 mg
1

Dose per serving from research: Omega-3 Fatty Acids

10 study groups in 9 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 60% of 10 study groups.

Daily doseStudy groups
50 mg or less
1
50 mg to 100 mg
2
100 mg to 250 mg
1
250 mg to 500 mg
0
500 mg to 1 g
6

Commonly used together

9 of 12 study groups took Zeaxanthin, Lutein and Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Docosahexaenoic Acid
6

12 study groups

Study
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
2 mg10 mg650 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
2 mg10 mg1 g1789 days—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg1 g5 years—
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
2 mg10 mg100 mg12 weeks96
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
2 mg10 mg100 mg24 weeks40
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
2 mg10 mg650 mg5 years—
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency
2014 · Multi · Healthy adults aged 18–32 years
26 mg8 mg190 mg120 days25
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
2 mg10 mg650 mg1 year50
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
1 mg10 mg30 mg1 year—
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
2 mg20 mg—1 year55
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
1 mg10 mg—1 year50
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg650 mg5 years—